Sovesudil phase II study published in Acta Ophthalmologica

Results testing sovesudil (PHP-201) in normal-tension glaucoma patients in a clinical study was published in the journal Acta Ophthalmologica. This study was funded by pH Pharma and was conducted at 15 clinical centres in South Korea. The study demonstrated the potential of sovesudil in providing intraocular pressure (IOP) reduction in...

Sovesudil neuroprotection results presented at WGC Annual Meeting

Results showing neuroprotection with sovesudil (PHP-201) was presented at the World Glaucoma Congress Annual Meeting June 30th - July 3rd, 2021 (WGC 2021). This study was conducted at The University of Melbourne as a collaboration with pH Pharma. The study demonstrated the potential of sovesudil in providing neuroprotection to neurons...

pH Pharma presents ADC proof-of-concept study results at AACR Annual Meeting

pH Pharma announced proof-of-concept (POC) study results on an antibody-drug conjugate (ADC) containing PH1, pH Pharma's novel toxin payload, at the Association for Cancer Research Annual Meeting April 10-14th, 2021 (AACR 2021). The study demonstrated the potential of PH1 as a potent anti-cancer warhead with immune-stimulatory effects. Highlights: Promising platform...

pH Pharma IND approval for “Alpha-1 Antitrypsin Deficiency treatment” Phase 2 clinical trial in Europe

PH Pharma, an innovative new drug research and development company, recently received final approval from the UK and Ireland authorities for the Phase 2 Clinical Trial to develop PHP-303 as the treatment for alpha-1 antitrypsin deficiency.(For more information, please refer to the link below) 

pH Pharma passed technical evaluation

Received “Pass” from two tech evaluation agencies… Target to file preliminary review application to KOSDAQExpanding global new drug development platform through IPO. Accelerating innovation for new drug development and business development(For more information, please refer to the link below)